It seems that sodium channel blockers, including phenytoin, can be effective in patients with GoF SCN8A mutations; however, due to potential cognitive impairment that is undesirable in patients with encephalopathy, phenytoin should be considered as a last-resort drug [27,28,29,30,31]. The gene discussed is SCN8A; the disease is Encephalopathy.